Allay Therapeutics

Today we announced that Nicole Vitullo - venture partner at @ArboretumVC - has joined the Allay board of directors: allaytx.com/allay-therapeu…

We are pleased to announce @Evonik has invested in our ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians. allaytx.com/news/

We are excited to present on our ATX-101 program designed to support recuperation from total knee replacement surgery at the 2022 @AAHKS Annual Meeting this week and to advance the discussion on ultra-sustained, controlled and targeted pain relief. allaytx.com

This month’s #AskAllay spotlight is Senior Manager of Quality Control, Yew Kee Lee, whose work involves ensuring that our ATX-101 and future pipeline products are tested in accordance to GMP practices.

Our latest #AskAllay spotlight is Wei Li Lee, a Ph.D. scientist with 10+ years in drug delivery R&D. At Allay, Wei leads a pipeline project focused on developing on-demand local anesthetic delivery systems to enhance post-surgical pain relief.

We were pleased to host our first ever Business of Biotech course for 28 high school students representing India, Japan, Dubai, Singapore and both U.S. coasts. Together we explored what it takes to develop, test, launch and market a new drug.

Our latest #AskAllay spotlight is R&D Manager Daniel Seet, who leads a team of engineers and scientists developing our pipeline of injectable pain management products. Daniel has been with us from the start and played a key role in advancing our lead program ATX-101.

This month’s #AskAllay spotlight is JJ Hancock, our Director of R&D. JJ joined Allay four years ago and is playing a key role in the development and characterization of ATX-101, our investigative product candidate designed to provide ultra-sustained post-surgical pain relief.

We’re excited to feature our Director of Non-Clinical, Esi Ghartey-Tagoe, PhD, in a new spotlight we’re calling #AskAllay. Esi oversees and manages our non-clinical research program to support proof-of-concept of our pipeline of products for opioid-free pain treatment.

Controlled delivery of analgesics is the basis of our platform that seeks to deliver long-lasting, local pain relief. Learn more about our platform here: allaytx.com/our-science/

Allay’s proprietary manufacturing combines highly validated drug and polymer components in new ways to target a range of therapeutic profiles.

Pain management innovation has stagnated for decades, and often involves constant re-dosing, clinical oversight and the use of systemic analgesics with major drawbacks – such as with opioids. But Allay is proposing a solution. Check out this thread to learn more!

Our CEO @AdamDGridley visited the Allay Singapore team to kick off 2022 & celebrate the Lunar New Year! He was able to meet many members of the Singapore team for the first time, visit local attractions, and connect with investors who have been supporting Allay. Take a look!

We’re pleased to welcome Ron Burch to Allay’s Scientific Advisory Board! Read the full announcement here: bit.ly/3AADYuy

Last week, we announced our new corporate headquarters in San Jose, California, cementing Allay’s presence in the Bay Area. Read more about the new headquarters and the expansion of our base of operations in Singapore: allaytx.com/news/?utm_sour…

Our scientific and clinical advisory board met recently to discuss Allay’s progress this past year and what 2022 will bring. Thank you to all of our dedicated advisory board members helping us shape the future of pain management!

Allay Therapeutics' CMO David Hewitt is participating in the @AAHKS annual meeting! #AAHKS2021

Congratulations to 2021 Nobel Laureates David Julius & Ardem Patapoutian, whose work has led to greater understanding of sensation and inspired the development of novel therapies to relieve pain. bit.ly/2YmlvTx

We're looking for a Senior Process Development Engineer! Learn more about the position and apply here: bit.ly/2YzgKGy